nicardipine Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1909 55985-32-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicardipine
  • (+/-)-Nicardipine
  • perpidine
  • nicardipine hydrochloride
  • nicardipine HCl
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
  • Molecular weight: 479.53
  • Formula: C26H29N3O6
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 1
  • TPSA: 111.01
  • ALOGS: -5.29
  • ROTB: 11

Drug dosage:

DoseUnitRoute
90 mg O
90 mg P

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1988 FDA CHIESI USA INC

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature baby 350.52 73.19 73 617 9978 4628324
Acute pulmonary oedema 286.49 73.19 50 640 2619 4635683
Foetal exposure during pregnancy 284.82 73.19 72 618 23097 4615205
Exposure during pregnancy 250.35 73.19 70 620 32901 4605401
Maternal exposure during pregnancy 244.06 73.19 60 630 17033 4621269
Foetal disorder 195.27 73.19 27 663 288 4638014
Low birth weight baby 174.47 73.19 33 657 2677 4635625
Premature delivery 171.98 73.19 35 655 4149 4634153
Neutropenia neonatal 127.43 73.19 16 674 73 4638229
Acute kidney injury 100.42 73.19 43 647 70388 4567914
Bradycardia 88.47 73.19 29 661 22540 4615762
Premature labour 75.23 73.19 16 674 2316 4635986
Blood pressure decreased 74.13 73.19 24 666 17876 4620426

Pharmacologic Action:

SourceCodeDescription
ATC C08CA04 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
FDA CS M0006414 Dihydropyridines
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Angina pectoris indication 194828000
Prinzmetal angina off-label use 87343002
Raynaud's phenomenon off-label use 266261006
Portal hypertension contraindication 34742003 DOID:10762
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Chronic idiopathic constipation contraindication 82934008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Cerebral hemorrhage contraindication 274100004
Cerebral infarction contraindication 432504007 DOID:3526
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.02 Basic
pKa2 2.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG/200ML (0.1MG/ML) CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 DISCN INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 DISCN INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER CHEMBL CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
Cytochrome P450 2C9 Enzyme IC50 6.55 WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 6.38 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.32 CHEMBL
Malate dehydrogenase cytoplasmic Enzyme IC50 4.30 CHEMBL
Adenosine receptor A3 GPCR Ki 5.49 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 4.78 CHEMBL
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.55 WOMBAT-PK
Adrenergic receptor alpha-2 GPCR IC50 5.85 CHEMBL
Equilibrative nucleoside transporter 1 Transporter Ki 5.27 CHEMBL
Beta-lactamase Enzyme IC50 4.70 CHEMBL
Adenosine receptor A3 GPCR Ki 4.96 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 5.44 CHEMBL
Adenosine receptor A2a GPCR Ki 4.20 CHEMBL
Voltage-gated L-type calcium channel Ion channel Ki 9.08 CHEMBL
Adenosine receptor A1 GPCR Ki 4.71 CHEMBL
Potassium voltage-gated channel subfamily A member 4 Unclassified BLOCKER IC50 6.10 IUPHAR

External reference:

IDSource
4019858 VUID
N0000147944 NUI
C0028005 UMLSCUI
D00617 KEGG_DRUG
108526002 SNOMEDCT_US
7396 RXNORM
372502001 SNOMEDCT_US
d00315 MMSL
4019858 VANDF
004518 NDDF
CZ5312222S UNII
4745 INN_ID
CHEMBL1484 ChEMBL_ID
DB00622 DRUGBANK_ID
CHEMBL1200326 ChEMBL_ID
54527-84-3 SECONDARY_CAS_RN
CHEBI:7550 CHEBI
D009529 MESH_DESCRIPTOR_UI
4474 PUBCHEM_CID
2559 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9542 INJECTION 2.50 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9593 INJECTION 2.50 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9633 INJECTION 0.20 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9634 INJECTION 0.10 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9689 INJECTION 25 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1020 CAPSULE 20 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1430 CAPSULE 30 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3204 INJECTION 2.50 mg INTRAVENOUS ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-9324 INJECTION 2.50 mg INTRAVENOUS ANDA 11 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-313 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 15 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-314 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 15 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-325 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 15 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 14593-124 INJECTION 2.50 mg INTRAVENOUS ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24658-750 CAPSULE 20 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24658-751 CAPSULE 30 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 40042-047 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 12 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-501 CAPSULE 20 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-502 CAPSULE 30 mg ORAL ANDA 11 sections
NICARDIPINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1428 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 17 sections
NICARDIPINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1482 INJECTION 25 mg INTRAVENOUS NDA 17 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55648-631 INJECTION 2.50 mg INTRAVENOUS ANDA 12 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 64679-631 INJECTION 2.50 mg INTRAVENOUS ANDA 13 sections
Cardene HUMAN PRESCRIPTION DRUG LABEL 1 68151-0089 CAPSULE, EXTENDED RELEASE 30 mg ORAL NDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68151-0092 CAPSULE 20 mg ORAL ANDA 11 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68151-0093 CAPSULE 30 mg ORAL ANDA 11 sections